Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.

Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) 在浓度为 0.0001 μg/mL 时，导致人表皮角质形成细胞 (HEK) 和人真皮成纤维细胞 (HDF) 的 MCP-1/CCL2 水平升高，当浓度为 0.001 μg/mL 或更高时，两种细胞的 MCP-1/CCL2 水平显著降低。
Vixarelimab (KPL-716) (0.0001-0.1 μg/mL) 预处理使得在 Oncostatin M（OSM）诱导的以及 OSM + IL-4 诱导的 HEK 和 HDF 细胞中，都降低了 MCP-1/CCL2 的水平，并且在浓度为 0.01 μg/mL 和 0.1 μg/mL 时观察到最大的效果。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Carl D Richards, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020 Jul 2;100(14):adv00197.  [Content Brief]